Biogen Inc
BIIB: XNAS (USA)
| Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
|---|---|---|---|
| $667.00 | Zrhh | Xfplbbhv |
Biogen's Neurology and Rare Disease Drugs Support a Wide Moat Despite Multiple Sclerosis Headwinds
/s3.amazonaws.com/arc-authors/morningstar/558ccc7b-2d37-4a8c-babf-feca8e10da32.jpg)
Business Strategy and Outlook
We think Biogen's specialty-market-focused drug portfolio and novel, neurology-focused pipeline create a wide moat. Biogen's strategy has its roots in the 2003 merger of Biogen (multiple sclerosis drug Avonex) and Idec (cancer drug Rituxan). Biogen is expanding its neurology portfolio beyond MS, including blockbuster neuromuscular disease drug Spinraza and recently launched Alzheimer's disease drug Leqembi.